<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250027</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL301_201</org_study_id>
    <nct_id>NCT02250027</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)</brief_title>
  <acronym>HL301</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose of HL301 in patients with acute
      bronchitis or acute exacerbations of chronic bronchitis.

      - BSS(Bronchitis Severity Score), BCSS(Breathlessness, Cough, and Sputum Scale), evaluation
      of symptoms of cough and sputum
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchitis Severity Score</measure>
    <time_frame>baseline(day 0) and day 7</time_frame>
    <description>Bronchitis Severity Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breathlessness, Cough, and Sputum Scale</measure>
    <time_frame>baseline(day 0) and day 7</time_frame>
    <description>Breathlessness, Cough, and Sputum Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of symptoms of cough and sputum</measure>
    <time_frame>baseline(day 0) and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total usage of acetaminophen</measure>
    <time_frame>baseline(day 0) and day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Acute Bronchitis</condition>
  <condition>Acute Exacerbations of Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>experimental A (0.6g/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental B (1.2g/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental C (1.8g/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo: 2 capsules at once, 3 times a day, for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL301 300mg capsule</intervention_name>
    <description>2 capsules at once, 3 times a day, for 7 days</description>
    <arm_group_label>experimental A (0.6g/day)</arm_group_label>
    <arm_group_label>experimental B (1.2g/day)</arm_group_label>
    <arm_group_label>experimental C (1.8g/day)</arm_group_label>
    <other_name>experimental A (0.6g/day) : HL301 300mg 2 capsule</other_name>
    <other_name>experimental B (1.2g/day) : HL301 300mg 4 capsule</other_name>
    <other_name>experimental C (1.8g/day) : HL301 300mg 6 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules at once, 3 times a day, for 7 days</description>
    <arm_group_label>experimental A (0.6g/day)</arm_group_label>
    <arm_group_label>experimental B (1.2g/day)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Microcrystalline Cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both gender, 19 years ≤ age ≤ 80 years

          2. Acute bronchitis or acute exacerbations of chronic bronchitis patients with
             BSS(Bronchitis Severity Score)* ≥ 5point at Visit1 and Visit2

          3. Written consent voluntarily to participate in this clinical trial

        Exclusion Criteria:

          1. Patients who were increased the bleeding tendency

          2. Patients with any of Alanine aminotransferase, Aspartate aminotransferase or serum
             Blood Urea Nitrogen, Creatinine&gt; 2 times of the normal upper range

          3. Patients who investigators determines to severe respiratory disease that would
             interfere with study assessment

          4. Patients with COPD(Chronic Obstructive Pulmonary Disease) history of stage 3 or more

          5. Patients who were treated with oral systemic adrenocortical hormone or
             immunosuppressive drug within 4 weeks prior to study participation

          6. Patients who were treated with oral β2-agonist, anticholinergic, Methylxanthine,
             antibiotics, antihistamines, sympathomimetic agent or oriental medicine/health
             functional food for antitussive and mucolytic Effect within 1 weeks prior to study
             participation

          7. Patients who were treated with oral Antitussive, Mucolytic Agents,systemic
             antimicrobial agent within 3 days prior to study medication dosing

          8. Patients with drug or alcohol abuse

          9. Patients with clinically significant active liver, renal, cardiovascular, respiratory,
             endocrine, central nervous system disease or history of malignant tumor or mental
             illness(except no relapse for 5 years after surgery)

         10. The aged person with severe medical history which is mental disorder(dementia),
             cancer, chronic renal failure, chronic liver failure

         11. Pregnant or breast-feeding

         12. Patients currently participating in or has participated in other clinical study within
             30 days prior to study participation

         13. Patients who investigators determines not appropriate to take part in this clinical
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute bronchitis</keyword>
  <keyword>acute exacerbations of chronic bronchitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

